Answers are grounded in this paper and cite their sources.
Type 1 cannabinoid receptors (CB 1 Rs) are expressed in the dorsal root ganglion (DRG) and contribute to the analgesic effect of cannabinoids. However, the epigenetic mechanism regulating the expression of CB 1 Rs in neuropathic pain is unknown. G9a (encoded by the Ehmt2 gene), a histone 3 at lysine 9 methyltransferase, is a key chromatin regulator responsible for gene silencing. In this study, we determined G9a's role in regulating CB 1 R expression in the DRG and in CB 1 R-mediated analgesic effects in an animal model of neuropathic pain. We show that nerve injury profoundly reduced mRNA levels of CB 1 Rs but increased the expression of CB 2 receptors in the rat DRG. ChIP results indicated increased enrichment of histone 3 at lysine 9 dimethylation, a G9a-catalyzed repressive histone mark, at the promoter regions of the CB 1 R genes. G9a inhibition in nerve-injured rats not only up-regulated the CB 1 R expression level in the DRG but also potentiated the analgesic effect of a CB 1 R agonist on nerve injury-induced pain hypersensitivity. Furthermore, in mice lacking Ehmt2 in DRG neurons, nerve injury failed to reduce CB 1 R expression in the DRG and to decrease the analgesic effect of the CB 1 R agonist. Moreover, nerve injury diminished the inhibitory effect of the CB 1 R agonist on synaptic glutamate release from primary afferent nerves to spinal cord dorsal horn neurons in WT mice but not in mice lacking Ehmt2 in DRG neurons. Our findings reveal that nerve injury diminishes the analgesic effect of CB 1 R agonists through G9a-mediated CB 1 R down-regulation in primary sensory neurons.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: